No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
PBYI240621P5000
- 2.10
- +0.22+11.70%
15min DelayClose Jun 20 16:00 ET
2.10High2.10Low
2.10Open1.88Pre Close30 Volume226 Open Interest5.00Strike Price6.30KTurnover850.04%IV2.68%PremiumJun 21, 2024Expiry Date2.02Intrinsic Value100Multiplier1DDays to Expiry0.08Extrinsic Value100Contract SizeAmericanOptions Type-0.7986Delta0.1964Gamma1.39Leverage Ratio-0.1296Theta-0.0001Rho-1.11Eff Leverage0.0005Vega
Intraday
- 5D
- Daily
News
Puma Biotechnology(PBYI.US) Director Sells US$33,528.33 in Common Stock
$Puma Biotechnology(PBYI.US)$ Director Stuglik Brian M sold 9,900 shares of common stock on Jun 13, 2024 at an average price of $3.3867 for a total value of $33,528.33.Source: Announcement What is sta
Puma Biotechnology(PBYI.US) Director Sells US$89,901.9 in Common Stock
$Puma Biotechnology(PBYI.US)$ Director WILSON TROY EDWARD sold 27,000 shares of common stock on Jun 13, 2024 at an average price of $3.3297 for a total value of $89,901.9.Source: Announcement What is
Puma Biotechnology(PBYI.US) Director Sells US$89,818.2 in Common Stock
$Puma Biotechnology(PBYI.US)$ Director Senderowicz Adrian sold 27,000 shares of common stock on Jun 13, 2024 at an average price of $3.3266 for a total value of $89,818.2.Source: Announcement What is
Puma Biotechnology(PBYI.US) Director Sells US$73,466.8 in Common Stock
$Puma Biotechnology(PBYI.US)$ Director MOYES JAY M sold 22,000 shares of common stock on Jun 13, 2024 at an average price of $3.3394 for a total value of $73,466.8.Source: Announcement What is stateme
Puma Biotechnology(PBYI.US) Director Sells US$37,096.4 in Common Stock
$Puma Biotechnology(PBYI.US)$ Director Dorval Allison sold 11,000 shares of common stock on Jun 13, 2024 at an average price of $3.3724 for a total value of $37,096.4.Source: Announcement What is stat
Investors Don't See Light At End Of Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Tunnel And Push Stock Down 33%
The Puma Biotechnology, Inc. (NASDAQ:PBYI) share price has fared very poorly over the last month, falling by a substantial 33%. Instead of being rewarded, shareholders who have already held through
Comments
$Puma Biotechnology(PBYI.US$
Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer
Puma Biotechnology (NASDAQ: PBYI) presented findings from a Phase I/Ib study of alisertib in advanced osimertinib-resistant EGFR-mutated non-small cell lung cancer (NSCLC) at the ASCO Annual Meeting. The study, involving 21 patients, found that intermittent dosing of alisertib (30 mg BID) with osimertinib (80 mg daily) was well-tolerate...
Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer
Puma Biotechnology (NASDAQ: PBYI) presented findings from a Phase I/Ib study of alisertib in advanced osimertinib-resistant EGFR-mutated non-small cell lung cancer (NSCLC) at the ASCO Annual Meeting. The study, involving 21 patients, found that intermittent dosing of alisertib (30 mg BID) with osimertinib (80 mg daily) was well-tolerate...
2
$Puma Biotechnology(PBYI.US$
Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)
Puma Biotechnology (NASDAQ: PBYI) presented promising findings from a Phase II study of alisertib for endocrine and CDK4/6 inhibitor-resistant, HER2-negative, hormone receptor-positive metastatic breast cancer at the 2024 ASCO Annual Meeting.
The study compared alisertib alone versus alisertib plus fulvestrant, show...
Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)
Puma Biotechnology (NASDAQ: PBYI) presented promising findings from a Phase II study of alisertib for endocrine and CDK4/6 inhibitor-resistant, HER2-negative, hormone receptor-positive metastatic breast cancer at the 2024 ASCO Annual Meeting.
The study compared alisertib alone versus alisertib plus fulvestrant, show...
$Puma Biotechnology(PBYI.US$ Reuters· 4 mins ago
Puma Biotechnology Inc - Jury Found '314 & '162 Patents to Be Infringed by AstraZeneca and Not Invalid, Awarded Plaintiffs $107.5 Mln in Damages
Puma Biotechnology Inc - Jury Found '314 & '162 Patents to Be Infringed by AstraZeneca and Not Invalid, Awarded Plaintiffs $107.5 Mln in Damages
1
Puma biotech buys licenses for oncology treatments that have gone through testing, and brings them to market. I will hold until the ticker hits my target range (7-8 USD,) reevaluate (using FA and TA, and current market conditions to determine price channel and optimize execution,) and trade out.
1
Read more